Heterocyclic NF-κB inhibitors

Details Heterocyclic NF-κB inhibitors Heterocyclic NF-κB inhibitors

2005-07-29

2010-10-12

Wilson, James O (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S374000, C514S385000, C514S427000, C548S146000, C548S215000, C548S300100, C548S400000

Reexamination Certificate

active

07812041

ABSTRACT:
The present invention relates to compounds of the general formula (I) and salts and physiologically functional derivatives thereof,whereinR1is independently hydrogen; alkyl, cycloalkyl, hydroxyalkyl, haloalkyl, haloalkyloxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl or substituted arylalkyl;R2is independently —NR3R4,R3is independently alkyl, cycloalkyl, alkoxy, alkylamine, —OH, —SH, alkylthio, hydroxyalkyl, haloalkyl, haloalkyloxy, aryl or heteroaryl,R4is independently alkyl, cycloalkyl, alkoxy, alkylamine, alkylthio, hydroxyalkyl, haloalkyl, haloalkyloxy, aryl or heteroaryl;R5is independently H, COR6, CO2R6, SOR6, SO3R6, alkyl, cycloalkyl, alkoxy, —NH2, alkylamine, —NR7COR6, halogen, —OH, —SH, alkylthio, hydroxyalkyl, haloalkyl, haloalkyloxy, aryl or heteroaryl;R6is independently H, alkyl, cycloalkyl, —NH2, alkylamine, aryl or heteroaryl;R7is independently H, alkyl, cycloalkyl, alkoxy, —OH, —SH, alkylthio, hydroxyalkyl, aryl, or heteroaryl;p is 0, or 1;q is 0, or 1;X is CO, or SO2.

REFERENCES:
patent: 5817677 (1998-10-01), Linz et al.
patent: 2006/0100224 (2006-05-01), Svenstrup et al.
patent: 102 08 256 (2003-09-01), None
patent: 102 08 256 (2003-09-01), None
patent: 1340757 (2003-09-01), None
patent: 1 352 650 (2003-10-01), None
patent: 1 516 777 (1968-02-01), None
patent: 2 270 848 (1975-12-01), None
patent: 1487007 (1977-09-01), None
patent: 97/15567 (1997-05-01), None
patent: WO 97/15567 (1997-05-01), None
patent: WO 02/064558 (2002-08-01), None
patent: 2004/014882 (2004-02-01), None
patent: WO 2004/014882 (2004-02-01), None
patent: 2004/018453 (2004-03-01), None
patent: WO 2004/018453 (2004-03-01), None
patent: 2004/041815 (2004-05-01), None
patent: WO 2004/041815 (2004-05-01), None
patent: 2004/058751 (2004-07-01), None
patent: WO 2004/058750 (2004-07-01), None
patent: WO 2004/058751 (2004-07-01), None
patent: 2005/003128 (2005-01-01), None
patent: WO 2005/003128 (2005-01-01), None
patent: 2005/058887 (2005-06-01), None
patent: WO 2005/058887 (2005-06-01), None
patent: WO 2005077924 (2005-08-01), None
patent: 2006/032322 (2006-03-01), None
patent: 2004/058750 (2006-07-01), None
Jantzen and Robinson. Modern Pharmaceutics, 1996, p. 596.
Marcu et al. Farmacia, 1962, 10(2), 87-91.
“Substructure search results”, http://www.sigmaaldrich.com/catalog/search/substructure/substructuresearchpage, accessed Feb. 20, 2009, attached as PDF.
International Search Report (dated Dec. 1, 2006).
Boger et al, “A New Class of Highly Cytotoxic Diketopiperazines”, Biorganic & Medicinal Chemistry Letters 10 (2000) pp. 1019, 1020.
Lange et al, “Synthesis of Highly Potent and Selective Hetaryl Ureas as Integrin . . . ”, Biorganic & Medicinal Chemistry Letters 12 (2002) pp. 1379-1382.
El-Subbagh et al, 2,4-Disubstituted thiazoles II., Eur J. Med Chem (1996), 31. pp. 1017-1021.
Rao et al, “Synthesis of Noval Thiazole-Containing DNA Minor Groove Binding Oligopeptides Related to the Antiobiotic Distamycin” J. Org. Chem., vol. 55, No. 2, p. 728-737.
Kumar et al, “Synthesis and Antitumor Cytotoxicity Evaluation of Novel Thiazole-Containing Glycosylated Polyamides”, Eur. J. Org. Chem, 2003, pp. 4842-4851.
Khalaf et al, “Distamycin Analogues with Enhances Lipophilicity: Synthesis and Antimicrobial Activity”, J. Med. Chem., 2004, vol. 47, No. 8, pp. 2133-2156.
Wipf et al, “Total Synthesis of (−)-Muscoride A”, J. Org. Chem. 1996, vol. 61, No. 19, pp. 6517-6522.
Boyce et al, “Naturally Occurring 4-Methylthiazolines. A Total Synthesis of (−)-[4R, 4S′]-Didehydromirabazole A”, Tetrahedron, 1995 vol. 51, No. 26, pp. 7313-7320.
Parsons, Jr. et al, Total Synthesis of (−)-Thiangazole, a Naturally-Occurring HIV-1 Inhibitor, J. Org. Chem., 1994, vol. 59, No. 17, pp. 4733-4734.
Wipf et al, “Total Synthesis of (−)-Thiangazole and Structrally Related Polyazoles” J. Org. Chem, 1995 vol. 60, No. 22, pp. 7224-7229.
Franchetti et al, “A New C-Nucleoside Analogue of Tiazofurin Synthesis and Biological Evaluation . . . ”, Bioorg. Med. Chem. Lett. (2001) 11, pp. 67-69.
Hahnemann et al, “On the Reaction of Thiazole-2,4-diamines with Isothiocyanates . . . ”, Helvetica Chimica Acta (2003) vol. 86, pp. 1949-1965.
Coqueron et al, “Iterativer Aufbau von Oxazolringen uber a-Chlorglycinate . . . ” Angew Chem. (2003)vol. 115, No. 12, pp. 1451-1454.
Wipf et al, “From Aziridines to Oxazolines and Thiazolines: The Heterocyclic Route to Thiangazole”, Synlett, (1997) pp. 1-10.
Das et al, “Thromboxane A2/endoperoxide Receptor Antagonists: 1,3-Dioxane and 1,3-Dioxolane Analogs” Bioorganic & Medicinal Chemistry Ltrs, (1993)vol. 3, No. 6, pp. 1271-1276.
Herrmann et al, “Chemical Modification of Thiangazole A in the Oxazole and Styryl Region”, Eur. J. Org., Chem. (1999), pp. 3381-3392.
European Patent Office Communication, Mar. 15, 2005.
International Search Report for PCT/EP2005/008261, Dated Oct. 11, 2005.
See Attached PTO / SB / 08B Non Patent Literature Documents.
Dale L. Boger, et al., “A new Class of Highly Cytotoxic Diketopiperazines”, Bioorganic & Medicinal Chemistry Letters, vol. 10, No. 10, XP-004204595, May 2000, pp. 1019-1020.
Udo E. W. Lange, et al., “Synthesis of Highly Potent and Selective Hetaryl Ureas as Integrin xv β3-Receptor Antagonists”, Bioorganic & Medicinal Chemistry Letters, vol. 12, XP-002289253, 2002, pp. 1379-1382.
Hi El-Subbagh, et al., “2,4-Disubstituted thiazoles II.* A novel class of antitumor agents, synthesis and biological evaluation” European Journal of Medicinal Chemistry, vol. 31, No. 12, XP-004071797, 1996, pp. 1017-1021.
K. Ekambareswara Rao, et al., Synthesis of Novel Thiazole-Containing DNA Minor Groove Binding Oligopeptides Related to the Antibiotic Distamycin, Journal of Organic Chemistry, American Chemical Society, vol. 55, No. 2, XP-002255609, 1990, pp. 728-737.
Rohtash Kumar, et al., “Synthesis and Antitumor Cytotoxicity Evaluation of Novel Thiazole-Containing Glycosylated Polyamides”, Eur. J. Org. Chem., vol. 24, XP-002346491, 2003. pp. 4842-4851.
Abedawn I. Khalaf, et al., “Distamycin Analogues with Enhanced Lipophilicity: Synthesis and Antimicrobial Activity”, J. Med. Chem., vol. 47, No. 8, XP-002346492, Mar. 5, 2004, pp. 2133-2156.
Peter Wipf, et al., “Total Synthesis of (−)-Muscoride A”, J. Org. Chem., vol. 61, XP-002199739, 1996, pp. 6517-6522.
Palmarisa Franchetti, et al., “A New C-Nucleoside Analogue of Tiazofurin: Synthesis and Biological Evaluation of 2-β-D-Ribofuranosylimidazole-4-carboxamide (Imidazofurin)”, Bioorganic & Medicinal Chemistry Letters, vol. 11, No. 1, XP-004225324, Jan. 8, 2001, pp. 67-69.
Richard J. Boyce, et al., “Naturally Occurring 4-Methylthiazolines. A Total Synthesis of (−)-[4R,4S′]-Didehydromirabazole A” vol. 51, No. 26, XP-002346493, 1995, pp. 7313-7320.
Rodney L. Parsons Jr., et al., “Total Synthesis of (−)-Thiangazole, a Naturally-Occurring HIV-1 Inhibitor”, J. Org. Chem., vol. 59, XP-002346494, pp. 4733-4734, 1994.
Peter Wipf, et al., “Total Synthesis of (−)-Thiangazole and Structurally Related Polyazoles”, J. Org. Chem., vol. 60, XP-002346495, 1995, pp. 7224-7229.
Cornelia Hahnemann, et al., “On the Reaction of Thiazole-2,4-diamines with Isothiocyanates-Preparation and Transformation of 2,4-Diaminothiazole-5-carbothioamides”, Helvetica Chimica Acta, vol. 86, XP-002346496, 2003, pp. 1949-1965.
Pierre-Yves Coqueron, et al., “Iterativer Aufbau von Oxazolringen über α-chlorglycinate: Totalsynthese von (−)-Muscorid A**”, Angewandte Chemie, vol. 115, No. 12, XP-002346497, 2003, pp. 1451-1454.
Peter Wipf, et al., “From Aziridines to Oxazolines and Thiazolines: The

Affiliated with

Also associated with

Rating

Heterocyclic NF-κB inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Heterocyclic NF-κB inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclic NF-κB inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4222871